UC Irvine Health

 

Insights from 2024 EHA Annual Meeting
C

EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in High-Risk CLL

By Insights from 2024 EHA Annual Meeting FEATURING Catherine Coombs
By Insights from 2024 EHA Annual Meeting FEATURING Catherine Coombs
68 views
June 28, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

05:11
Pharmacosmos Hematology

A discussion on the safety of an IV iron replacement therapy

Feat. H. Bahrain

Featured Video

04:26
Pharmacosmos Hematology

An Introduction to an IV iron replacement therapy

Feat. H. Bahrain
Videos
05:41
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in H…

Feat. C. Coombs
11:26
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Study EV-103 - Neoadjuvant Enfortumab Ved…

Feat. N. Mar
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
13:21
UC Irvine Health

GU Treatment Updates: Standard of Care 5-Year Follow-Up Data From th…

Feat. N. Mar
13:15
UC Irvine Health

GU Treatment Updates: mCRPC Therapy Options and Clinical Application…

Feat. N. Mar
16:16
Insights from 2023 EHA® Annual Meeting

Experts Discuss Key Updates in CLL From EHA and iCML

Feat. S. O'Brien, C. Coombs
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
06:27
UC Irvine Health

S1918: Randomized Phase 2/3 Study of R-miniCHOP +/- Oral Azacitidine…

Feat. E. Brem
10:29
UC Irvine Health

Molecular Characteristics of Advanced ccRCC Harboring TERT Mutations

Feat. N. Mar
24:37
Indy Hematology Review

Recent Updates on the Treatment of Polycythemia Vera

Feat. A. Fleischman
16:23
Indy Hematology Review

Updates on the Treatment of Myelofibrosis and FGFR-Mutated Myeloid N…

Feat. A. Fleischman
12:17
UC Irvine Health

Work-Up and Prescribing Patterns in Real World Management of Patient…

Feat. N. Mar